Current Hepatitis Reports

, Volume 3, Issue 1, pp 38–43 | Cite as

Mechanisms of drug resistance to current and future antiviral therapies for hepatitis C virus infection

  • Jean-Michel Pawlotsky
Article

Abstract

The treatment of chronic hepatitis C is currently based on the pegylated interferon alpha and ribavirin combination. Despite this treatment, a significant number of patients still fail to eradicate the virus. The mechanisms underlying this failure are unknown, but indirect evidence suggests that chronic infection is associated with phenomena that protect hepatitis C virus (HCV) from the antiviral action of interferon alpha and hinder the clearance of infected cells. Viral factors responsible for true "HCV resistance" probably play a partial role. Numerous new HCV drugs are currently at the developmental stage. It is foreseeable that specific HCV inhibitors will select resistant viral variants. As a result, combination therapy will probably become the standard of care in chronic hepatitis C.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    McHutchison J, Davis GL, Esteban-Mur R, et al.: Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon alfa-2b alone or in combination with ribavirin. Hepatology 2001, 34:244A.Google Scholar
  2. 2.
    National Institutes of Health: National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10–12, 2002. Hepatology 2002, 36(5 suppl 1):S3-S20.CrossRefGoogle Scholar
  3. 3.
    Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975–982.PubMedCrossRefGoogle Scholar
  4. 4.
    Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958–965.PubMedCrossRefGoogle Scholar
  5. 5.
    Pawlotsky JM: Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res 2003, 59:1–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Lam NP, Neumann AU, Gretch DR, et al.: Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997, 26:226–231.PubMedCrossRefGoogle Scholar
  7. 7.
    Zeuzem S, Herrmann E, Lee JH, et al.: Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001, 120:1438–1447.PubMedCrossRefGoogle Scholar
  8. 8.
    Neumann AU, Lam NP, Dahari H, et al.: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferonalpha therapy. Science 1998, 282:103–107.PubMedCrossRefGoogle Scholar
  9. 9.
    Simmonds P: Viral heterogeneity of the hepatitis C virus. J Hepatol 1999, 31(suppl 1):54–60.PubMedCrossRefGoogle Scholar
  10. 10.
    Witherell GW, Beineke P: Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response. J Med Virol 2001, 63:8–16.PubMedCrossRefGoogle Scholar
  11. 11.
    Enomoto N, Sakuma I, Asahina Y, et al.: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996, 334:77–81.PubMedCrossRefGoogle Scholar
  12. 12.
    Enomoto N, Sakuma I, Asahina Y, et al.: Comparison of fulllength sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995, 96:224–230.PubMedCrossRefGoogle Scholar
  13. 13.
    Nousbaum J, Polyak SJ, Ray SC, et al.: Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 2000, 74:9028–9038.PubMedCrossRefGoogle Scholar
  14. 14.
    Herrmann E, Lee HJ, Marinos G, et al.: Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003, 37:1351–1358.PubMedCrossRefGoogle Scholar
  15. 15.
    Pawlotsky JM, Brillet R, Penin F, et al.: Does nonstructural 5A (NS5A) protein mediate HCV genotype 1 resistance to interferon (IFN) alfa-based therapy by antagonizing IFN antiviral effect? Hepatology 2002, 36:283A.CrossRefGoogle Scholar
  16. 16.
    Heim MH, Moradpour D, Blum HE: Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol 1999, 73:8469–8475.PubMedGoogle Scholar
  17. 17.
    Blindenbacher A, Duong FH, Hunziker L, et al.: Expression of hepatitis C virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology 2003, 124:1465–1475. Describes inhibition of the Jak-Stat pathway upstream of PKR by the HCV polyprotein expressed in transgenic mice.PubMedCrossRefGoogle Scholar
  18. 18.
    Taylor DR, Shi ST, Romano PR, et al.: Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999, 285:107–110.PubMedCrossRefGoogle Scholar
  19. 19.
    Vyas J, Elia A, Clemens MJ: Inhibition of the protein kinase PKR by the internal ribosome entry site of hepatitis C virus genomic RNA. RNA 2003, 9:858–870.PubMedCrossRefGoogle Scholar
  20. 20.
    Gale M Jr, Blakely CM, Kwieciszewski B, et al.: Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998, 18:5208–5218.PubMedGoogle Scholar
  21. 21.
    Gale M Jr, Kwieciszewski B, Dossett M, et al.: Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol 1999, 73:6506–6516.PubMedGoogle Scholar
  22. 22.
    Polyak SJ, Paschal DM, McArdle S, et al.: Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology 1999, 29:1262–1271.PubMedCrossRefGoogle Scholar
  23. 23.
    Polyak SJ, Khabar KS, Rezeiq M, Gretch DR: Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol 2001, 75:6209–6211.PubMedCrossRefGoogle Scholar
  24. 24.
    Polyak SJ, Khabar KS, Paschal DM, et al.: Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 2001, 75:6095–6106. Provides the first demonstration that NS5A transcriptional activation may be functional during infection. It suggests that NS5A transcriptional activation of the interleukin-8 gene may play a role in IFN alpha treatment failure, through mechanisms that remain to be elucidated.PubMedCrossRefGoogle Scholar
  25. 25.
    Foy E, Li K, Wang C, et al.: Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003, 300:1145–1148. On the basis of in vitro experiments, this article suggests that the IFN regulatory factor-3 could be inhibited by the HCV NS3 serine proteinase and that this would constitute a mean by which the virus would antagonize IFN antiviral effect. It is not known whether such an interaction exists in vivo and plays a role in IFN alpha treatment failure.PubMedCrossRefGoogle Scholar
  26. 26.
    Goutagny N, Fatmi A, De Ledinghen V, et al.: Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection. J Infect Dis 2003, 187:1951–1958. Demonstrates that HCV can replicate in dendritic cells.PubMedCrossRefGoogle Scholar
  27. 27.
    Jinushi M, Takehara T, Kanto T, et al.: Critical role of MHC class I-related chain A and B expression on IFN-alphastimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. J Immunol 2003, 170:1249–1256. Shows that natural killer cell activation is impaired during HCV infection.PubMedGoogle Scholar
  28. 28.
    Jaeckel E, Cornberg M, Wedemeyer H, et al.: Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001, 345:1452–1457.PubMedCrossRefGoogle Scholar
  29. 29.
    Pawlotsky JM, Germanidis G, Frainais PO, et al.: Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. J Virol 1999, 73:6490–6499.PubMedGoogle Scholar
  30. 30.
    Pawlotsky JM, Germanidis G, Neumann AU, et al.: Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations. J Virol 1998, 72:2795–2805.PubMedGoogle Scholar
  31. 31.
    Soler M, Pellerin M, Malnou CE, et al.: Quasispecies heterogeneity and constraints on the evolution of the 5′ noncoding region of hepatitis C virus (HCV): relationship with HCV resistance to interferon-alpha therapy. Virology 2002, 298:160–173.PubMedCrossRefGoogle Scholar
  32. 32.
    Soler M, Penin F, Ray S, et al.: Hepatitis C virus NS3 serine protease variability and evolution are strongly constrained by the need for structural and functional conservation [abstract]. J Hepatol 2002, 36(suppl 1):5. Describes HCV NS3 proteinase natural variability and suggests that the NS3 proteinase, an obvious target for specific HCV inhibitors, could be prone to the selection of resistant variants by these drugs.CrossRefGoogle Scholar
  33. 33.
    Querenghi F, Yu Q, Billaud G, et al.: Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy. J Viral Hepat 2001, 8:120–131.PubMedCrossRefGoogle Scholar
  34. 34.
    Shiffman ML: Retreatment of patients with chronic hepatitis C. Hepatology 2002, 36:S128–134.PubMedCrossRefGoogle Scholar
  35. 35.
    Chapman BA, Stace NH, Edgar CL, et al.: Interferon-alpha2a/ ribavirin versus interferon-alpha2a alone for the retreatment of hepatitis C patients who relapse after a standard course of interferon. N Z Med J 2001, 114:103–104.PubMedGoogle Scholar
  36. 36.
    Young KC, Lindsay KL, Lee KJ, et al.: Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 2003, 38:869–878. This is an intriguing article suggesting that ribavirin selects resistant variants when administered for several months in HCV-infected patients. These data need to be confirmed.PubMedGoogle Scholar
  37. 37.
    Bronowicki JP, Ouzan D, Asselah T, et al.: Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2a (40 kD) (Pegasys) alone versus peginterferon alfa-2a (40kD) plus ribavirin (Copegus) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of peginterferon alfa-2a (40 kD) plus ribavirin: an open, multicenter randomized trial. Hepatology 2003, 38:244A.CrossRefGoogle Scholar
  38. 38.
    Pawlotsky JM, McHutchison JG: Hepatitis C new drug and clinical trials development: promises and pitfalls. Hepatology 2004, in press. Summarizes a recent Single Topic Conference organized by the American Association for the Study of Liver Diseases at which the current therapeutic approaches in preclinical and clinical development for HCV have been presented.Google Scholar
  39. 39.
    Martell M, Esteban JI, Quer J, et al.: Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992, 66:3225–3229.PubMedGoogle Scholar
  40. 40.
    Weiner AJ, Brauer MJ, Rosenblatt J, et al.: Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991, 180:842–848.PubMedCrossRefGoogle Scholar
  41. 41.
    Trozzi C, Bartholomew L, Ceccacci A, et al.: In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 2003, 77:3669–3679.PubMedCrossRefGoogle Scholar
  42. 42.
    Lin C, Lin K, Gates CA, et al.: VX-950, a HCV protease inhibitor, retains potency against BILN-2061 resistant replicon cells [abstract]. Hepatology 2003, 38:638A. Describes the in vitro selection of resistant proteinases by two specific inhibitors of the NS3 serine proteinase currently at the preclinical or clinical developmental phase.CrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2004

Authors and Affiliations

  • Jean-Michel Pawlotsky
    • 1
  1. 1.Service de VirologieHôpital Henri MondorCréteilFrance

Personalised recommendations